Longevity market poised for growth as AI and genomics accelerate developments
Global analysis projects the longevity market will exceed US$740 billion in 2026, driven by AI, genomics and regenerative medicine; the sector is shifting from consumer wellness toward healthcare-aligned solutions supported by insurers, employers, health systems and pharmaceutical firms. Demand for integrated platforms for early risk detection, biomarker profiling, remote monitoring and longevity clinics is rising, but regulatory ambiguity about ageing as a medical condition, reimbursement hurdles and high testing costs could limit adoption.
Why it mattersUS$740 billion projection and insurer interest mean startups must prioritise payer-aligned biomarker validation.